H. Lundbeck A/S (Lundbeck) reports second quarter revenue of DKK 4,100 million growing 9% compared to the same period last year. In constant exchange rates revenue for the quarter increased 13%.

Eli Lilly and Company (NYSE: LLY) announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion. The review includes summaries of previously published information; new, previously unpublished observations; and new data on EVISTA use.

Data presented at the American Association for Clinical Chemistry (AACC) meeting showed that many people have low vitamin D levels and that testing individuals at risk may be beneficial.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint.

Bristol-Myers Squibb Company (NYSE: BMY) announced double-digit sales growth in a quarter that was highlighted by important new product approvals in both the U.S. and Europe, and key data from the Company's cardiovascular, oncology and diabetes franchises.

The National Comprehensive Cancer Network® (NCCN®) announces the development of the first continuing medical education (CME) program to leverage data in the NCCN Oncology Outcomes Database (NCCN Database) to objectively measure the impact of comprehensive performance improvement on patient outcomes.

Pfizer Inc. (NYSE: PFE) today reported financial results for second-quarter 2011. Second-quarter 2011 revenues were $17.0 billion, a decrease of 1% compared with the year-ago quarter.